You have read all your free articles, to continue reading subscribe to read the rest of this content.
Genmab and argenx have entered into a collaboration agreement to jointly discover, develop and commercialize novel therapeutic antibodies with applications in immunology, as well as in oncology therapeutic areas. The multiyear collaboration will leverage the antibody engineering expertise and knoAlready a subscriber Login You have read all your free articles,…
AstraZeneca’s Farxiga (dapagliflozin) has been granted Priority Review in the US for the treatment of new or worsening chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D). The Food and Drug Administration (FDA) grants Priority Review to regulatory submissions for medAlready a subscriber Login You have read all your…
AstraZeneca's Q1 2016 results include a total revenue growth by 5 %, driven by a significant increase in externalization Revenue and the results are in line with expectations. The company's core R&D costs increased by 15%, reflecting recent acquisitions and the Core R&D costs declined veAlready a subscriber Login You have…
The winner of the Start-up Slam: Sweden, a pitching competition, taking place at BIO-Europe Spring in Stockholm for the first time, was QureTech Bio AB, a start-up developing first line drugs to combat antibiotic resistance and infectious diseases. This session at the event was co-sponsored by KaAlready a subscriber Login…
